Knee Osteoarthritis: Clinical and MRI Outcomes After Multiple Intra-Articular Injections With Expanded Autologous Adipose-Derived Stromal Cells or Platelet-Rich Plasma

• Published in: Cartilage Vol. 14; no. 4; pp. 433 - 444
• Main Authors: Khoury, Miguel A., Chamari, Karim, Tabben, Montassar, Alkhelaifi, Khalid, Papacostas, Emmanuel, Marín Fermín, Theodorakys, Laupheimer, Markus, D′Hooghe, Pieter
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.12.2023
• Subjects: Clinical Research; Humans; Injections, Intra-Articular; Magnetic Resonance Imaging; Osteoarthritis, Knee - drug therapy; Osteoarthritis, Knee - therapy; Pain - drug therapy; Platelet-Rich Plasma; Retrospective Studies; Stromal Cells; Treatment Outcome; stem cells; intra-articular injection; cartilage injury; osteoarthritic knee pain; adipose-derived stromal cells
• ISSN: 1947-6035; 1947-6043; 1947-6043
• DOI: 10.1177/19476035231166127

Objective To directly compare clinical and MRI outcomes of multiple intra-articular injections of adipose-derived stromal cells (ASCs) or platelet-rich plasma (PRP) in patients with knee osteoarthritis (OA). Design We retrospectively compared 24-month outcomes in (1) 27 patients receiving 3-monthly intra-articular injections with a total of 43.8 million ASCs and (2) 23 patients receiving 3-monthly injections of 3-ml preparation of PRP. All patients had Kellgren-Lawrence grade 1, 2, or 3 knee OA with failed conservative medical therapy. The Numeric Pain Rating Scale (NPRS) scores; Knee injury and Osteoarthritis Outcome Score (KOOS) at baseline, 6, 12, and 24 months after the first injection; and the MRI Osteoarthritis Knee Score (MOAKS) at 12 and 24 months were considered as outcomes. Results No major complications occurred in any patient. Both groups significantly improved in pain NPRS score and KOOS at 6 months. At 12- and 24-month evaluations, the ASC group significantly decreased scores to a greater degree (P < 0.001) than the PRP group. MOAKS scores indicated a decrease in disease progression in the ASC group. Conclusion Both ASCs and PRP were safe and resulted in clinical improvement in patients with knee OA at 6 months; however, at 12 and 24 months, ASCs outperformed leukocyte-poor PRP in clinical and radiological outcomes.